Hamlins is delighted to announce that it has acted for longstanding client Hybridan LLP as Broker and new client Spark Advisory Partners as nominated adviser on a successful fundraising for Integumen plc, the biotech company traded on the London Stock Exchange’s AIM market in connection with the acquisition of a 9.35% stake in Cellulac plc by Integumen.
Integumen has conditionally raised approximately £700,000 through the issue of Shares to new and existing investors.
The net proceeds of the fundraise will fund the promotion of the product range, product approval applications and additional working capital to the Company. In addition, heads of terms in respect of a licence agreement were entered into between Integumen and Cellulac.
The transaction also involved a share subdivision and alteration to the articles of association of Integumen, a general meeting and warrant issue.
Hybridan, the well-known small cap broker is a longstanding client of the firm. This is the first instruction for the firm from Spark with whom Hamlins has worked on several AIM transactions previously and shares a number of clients.
Head of Corporate Daniel Bellau led the Hamlins team, assisted by corporate associate Lisa Faragher.
Daniel Bellau commented “We were delighted to assist our longstanding client Hybridan with this fundraising and to work for, rather than opposite, Spark with whom we have worked on deals before.“
The Hamlins Corporate team which has an enviable reputation in the junior equity markets, regularly advises on IPOs, fundraisings and transactions on the Official List, AIM and NEX.
Find out more about our Corporate Team